OUR SPEAKERS
KEVIN
ENTWISTLE
DANA
SULLIVAN
VP – PRECISION MEDICINE STRATEGY SERVICES
PRINCIPAL – PRECISION MEDICINE STRATEGY
Kevin Entwistle has over 15 years of experience working in the pharmaceutical industry and supporting global leaders to develop impactful commercialization strategies for the launch of precision medicines. He has previously worked for Qiagen, Leica Biosystems and J&J. Kevin’s expertise extends across multiple indications including oncology, neurology, immunology, cardiovascular and rare diseases.
As VP of Scientific & Advisory Services at Diaceutics, Kevin utilizes his extensive experience and Diaceutics’ real-world data to provide pharmaceutical and biotech customers with a deep understanding of the current precision medicine landscape and the strategic guidance required to successfully launch therapies to market, enhancing patient outcomes and driving the adoption of precision medicines.
Dana is a Precision Medicine leader with over 15 years of experience across diagnostics, pharma, and biotech. As Principal at Diaceutics, she partners with clients to shape and execute diagnostic commercialization strategies —supporting CDx development and partnerships, patient identification, customer engagement strategies, launch planning, and life cycle management initiatives. Dana brings deep insight into evolving marketing landscapes, helping pharma and biotech teams align diagnostics with strategic goals and deliver value across oncology and rare disease.
Precision medicine promises transformative outcomes but its adoption is often slowed by strategies which may not consider the diagnostic test.
Diaceutics' team of in-house Precision Medicine experts designed the 6A™ Strategic Framework, now widely used across the industry to illuminate hidden barriers and highlight opportunities for commercial success. Join us in this webinar to discover how the framework can guide your brand to faster, more successful uptake.
Learn how to ensure your existing strategy is precision medicine ready and build tactical strategies rooted in real world actionable insights, and explore how to harness AI effectively while avoiding common pitfalls. Whether you're preparing for launch or optimizing post-launch performance, this session offers practical tools and expert guidance to accelerate adoption and maximize impact.
KEY LEARNINGS
Use AI Wisely: Explore how to integrate AI into your strategy while avoiding common missteps that can derail adoption.
Engage with Experts: Gain insights from seasoned professionals with a track record of successful precision medicine launches —and get your questions answered live.
Uncover Hidden Barriers: Learn how the 6A Strategic Framework reveals adoption challenges that traditional approaches for precision medicine often miss.
Access Precision Medicine Commercialisation Expertise:
Understand how deep domain knowledge and strategic insights in precision medicine can drive smarter, more targeted brand strategies.
Build Insight-Driven Strategies: Discover how to move from assumptions to evidence-based tactical planning for precision medicine commercialisation.
FROM INSIGHT TO IMPACT:
ACCELERATING PRECISION MEDICINE ADOPTION WITH THE 6A™ STRATEGIC FRAMEWORK
Kevin Entwistle & Dana Sullivan
11 September
11AM ET
ABOUT US
At Diaceutics we believe that every patient should have access to the right treatment at the right time to positively impact their disease outcome, and we are committed to solving commercialization challenges.
We provide the world's leading pharma and biotech companies with an end-to-end commercialization solution for the launch of precision medicine through our platform
DXRX - The Diagnostic Network®
Copyright © 2024, Diaceutics. All rights reserved
GUEST SPEAKERS
Amy Gorman is the International Precision Medicine & Diagnostics Oncology Commercial Leader at AbbVie. She has two decades of oncology industry experience spanning diagnostics, device, and pharma in both medical affairs and commercial. Her work has focused on solid tumors, malignant hematology, and rare disease; with a passion towards shaping strategy for Precision Medicine to drive meaningful impact for patients. Prior to her time in oncology industry, Amy spent five years in the lab focused on pathology as a Cytologist.
International Precision Medicine & Diagnostics Oncology Commercial Leader, AbbVie
AMY GORMAN
WATCH WEBINAR RECORDING
SUBMIT YOUR DETAILS TO WATCH THE RECORDING
WEBINAR
Watch our latest
on demand